Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

1.

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.

Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA.

J Clin Oncol. 2008 Mar 10;26(8):1316-23. doi: 10.1200/JCO.2007.13.6374.

PMID:
18323556
[PubMed - indexed for MEDLINE]
Free Article
2.

Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy.

Ng CS, Charnsangavej C, Wei W, Yao JC.

AJR Am J Roentgenol. 2011 Mar;196(3):569-76. doi: 10.2214/AJR.10.4455.

PMID:
21343498
[PubMed - indexed for MEDLINE]
3.

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.

Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS.

Cancer Chemother Pharmacol. 2011 Aug;68(2):293-300. doi: 10.1007/s00280-010-1478-7. Epub 2010 Oct 20.

PMID:
20960192
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.

Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K.

Cancer. 2012 Jul 1;118(13):3302-10. doi: 10.1002/cncr.26648. Epub 2011 Nov 9.

PMID:
22072099
[PubMed - indexed for MEDLINE]
Free Article
5.

Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.

Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R.

Am J Gastroenterol. 1999 May;94(5):1381-7.

PMID:
10235222
[PubMed - indexed for MEDLINE]
6.

A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.

Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, Wu H, Lesinski GB, Kendra K, Chen HX, Walker MJ, Carson WE 3rd.

Ann Surg Oncol. 2007 Aug;14(8):2367-76. Epub 2007 May 30.

PMID:
17534686
[PubMed - indexed for MEDLINE]
7.

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ.

J Clin Oncol. 2008 Nov 20;26(33):5422-8. doi: 10.1200/JCO.2008.16.9847. Epub 2008 Oct 20.

PMID:
18936475
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma.

Vihinen PP, Hernberg M, Vuoristo MS, Tyynelä K, Laukka M, Lundin J, Ivaska J, Pyrhönen S.

Melanoma Res. 2010 Aug;20(4):318-25. doi: 10.1097/CMR.0b013e3283390365.

PMID:
20375744
[PubMed - indexed for MEDLINE]
9.

FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.

Summers J, Cohen MH, Keegan P, Pazdur R.

Oncologist. 2010;15(1):104-11. doi: 10.1634/theoncologist.2009-0250. Epub 2010 Jan 8.

PMID:
20061402
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma.

Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K.

Int J Clin Oncol. 2011 Jun;16(3):221-9. doi: 10.1007/s10147-010-0151-9. Epub 2010 Dec 4.

PMID:
21132451
[PubMed - indexed for MEDLINE]
11.

Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma.

Frampton JE, Keating GM.

BioDrugs. 2008;22(2):113-20. Review.

PMID:
18345708
[PubMed - indexed for MEDLINE]
12.

A pilot study of bevacizumab and interferon-α2b in ocular melanoma.

Guenterberg KD, Grignol VP, Relekar KV, Varker KA, Chen HX, Kendra KL, Olencki TE, Carson WE 3rd.

Am J Clin Oncol. 2011 Feb;34(1):87-91. doi: 10.1097/COC.0b013e3181d2ed67.

PMID:
20458209
[PubMed - indexed for MEDLINE]
13.

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V.

J Clin Oncol. 2010 May 1;28(13):2144-50. doi: 10.1200/JCO.2009.26.7849. Epub 2010 Apr 5.

PMID:
20368553
[PubMed - indexed for MEDLINE]
Free Article
14.

Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.

Del Vecchio M, Mortarini R, Canova S, Di Guardo L, Pimpinelli N, Sertoli MR, Bedognetti D, Queirolo P, Morosini P, Perrone T, Bajetta E, Anichini A.

Clin Cancer Res. 2010 Dec 1;16(23):5862-72. doi: 10.1158/1078-0432.CCR-10-2363. Epub 2010 Oct 28. Erratum in: Clin Cancer Res. 2011 Feb 1;17(3):630.

PMID:
21030496
[PubMed - indexed for MEDLINE]
Free Article
15.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators.

Lancet. 2007 Dec 22;370(9605):2103-11.

PMID:
18156031
[PubMed - indexed for MEDLINE]
16.

Bevacizumab in non-small cell lung cancer.

Di Costanzo F, Mazzoni F, Micol Mela M, Antonuzzo L, Checcacci D, Saggese M, Di Costanzo F.

Drugs. 2008;68(6):737-46. Review.

PMID:
18416583
[PubMed - indexed for MEDLINE]
17.

Hepatic arterial infusion chemotherapy in combination with pegylated interferon-α-2b for advanced hepatocellular carcinoma.

Okita K, Yamasaki T, Hamabe S, Saeki I, Harima Y, Terai S, Sakaida I.

Hepatogastroenterology. 2012 Mar-Apr;59(114):533-7. doi: 10.5754/hge10013.

PMID:
22353519
[PubMed - indexed for MEDLINE]
18.

A phase II study of docetaxel in patients with metastatic carcinoid tumors.

Kulke MH, Kim H, Stuart K, Clark JW, Ryan DP, Vincitore M, Mayer RJ, Fuchs CS.

Cancer Invest. 2004;22(3):353-9.

PMID:
15493355
[PubMed - indexed for MEDLINE]
19.

Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.

George S, Hutson TE, Mekhail T, Wood L, Finke J, Elson P, Dreicer R, Bukowski RM.

Cancer Chemother Pharmacol. 2008 Jul;62(2):347-54. Epub 2007 Oct 2.

PMID:
17909807
[PubMed - indexed for MEDLINE]
20.

A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.

Grignol VP, Olencki T, Relekar K, Taylor C, Kibler A, Kefauver C, Wei L, Walker MJ, Chen HX, Kendra K, Carson WE 3rd.

J Immunother. 2011 Jul-Aug;34(6):509-15. doi: 10.1097/CJI.0b013e31821dcefd.

PMID:
21654521
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk